Personalized medicine is a medical approach that uses your genetic makeup, lifestyle, and environment to tailor prevention, diagnosis, and treatment decisions specifically to you. Rather than relying on one-size-fits-all treatments designed for the average patient, it matches therapies to the biological characteristics that make you different from everyone else. In 2024, roughly 38% of all new drugs approved by the FDA were classified as personalized medicines, up from 35% the year before, a trend that reflects how central this approach has become to modern healthcare.
Precision Medicine vs. Personalized Medicine
You’ll often see the terms “personalized medicine” and “precision medicine” used interchangeably. They mean essentially the same thing, though the National Research Council has expressed a preference for “precision medicine.” The concern was that “personalized” might imply every treatment is built from scratch for a single individual. In practice, precision medicine groups patients by shared genetic, environmental, and lifestyle factors, then identifies which existing approaches work best for each group. The distinction is mostly semantic, and both terms appear across medical literature and patient-facing resources.
How Your Genes Change Drug Response
The core insight behind personalized medicine is simple: the same drug at the same dose can work perfectly in one person, do nothing in another, and cause dangerous side effects in a third. Much of that variation traces back to your DNA. Genetic differences alter how your body processes medications in two key ways.
First, some drugs need to be converted into their active form by enzymes in your body. If you carry gene variants that reduce or eliminate the function of those enzymes, the drug never fully activates. Codeine, for example, must be converted in the body before it relieves pain. People who lack the enzyme responsible for that conversion get little to no benefit from it. The blood thinner clopidogrel and the breast cancer drug tamoxifen work the same way: without the right enzyme activity, they underperform.
Second, some drugs are broken down and cleared from your body by a single metabolic pathway. If that pathway is impaired due to genetic variation, the drug builds up to dangerously high levels. Warfarin, one of the most widely prescribed blood thinners, is a classic example. Studies have shown that common genetic variants in just two genes account for about 34% of the variability in the dose a patient needs. Too much warfarin causes uncontrolled bleeding; too little leaves a patient vulnerable to clots. Genetic testing helps clinicians find the right dose faster.
Some genetic variants don’t affect drug metabolism at all but instead trigger severe immune reactions. People who carry a specific gene variant called HLA-B*5701 face a risk of potentially fatal skin reactions when taking the HIV drug abacavir. A simple genetic test before prescribing the drug eliminates that risk entirely. Similar testing exists for the epilepsy drug carbamazepine, where a variant more common in people of Asian descent is linked to the same type of dangerous reaction.
Cancer Treatment as the Leading Example
Oncology is where personalized medicine has made its most visible impact. Tumors are driven by specific genetic mutations, and identifying those mutations allows doctors to select drugs designed to target them directly. In 2011, the FDA approved crizotinib for lung cancer alongside a companion diagnostic test that identifies patients whose tumors carry a specific gene rearrangement called ALK. Only patients who test positive are candidates for the drug. In 2021, the FDA approved sotorasib for non-small cell lung cancer driven by a particular KRAS mutation, a target that scientists had considered “undruggable” for decades.
These targeted therapies depend on companion diagnostics: tests that determine whether a patient’s cancer has the specific molecular feature a drug is designed to treat. The FDA defines a companion diagnostic as a device that provides information essential for the safe and effective use of a corresponding drug. These tests identify who is most likely to benefit, who faces increased risk of side effects, and how a patient is responding to treatment over time. The FDA has encouraged drug companies to develop companion diagnostics alongside new therapies from the earliest stages of drug development, so that when a drug is approved, the matching test is ready.
Liquid Biopsies and Faster Diagnoses
Getting the genetic information needed to guide treatment has become faster and less invasive. Traditional tissue biopsies require a needle or surgical procedure to collect a sample directly from a tumor. Liquid biopsies, by contrast, analyze fragments of tumor DNA circulating in a simple blood draw.
In non-small cell lung cancer, liquid biopsies return results an average of 27 days faster than tissue biopsies. They also have higher testing success rates. A liquid-first approach identified the biomarkers needed to guide treatment in 76.5% of patients, compared to 54.9% with a tissue-first approach. The two methods agreed on results 95% to 100% of the time for key biomarkers, and there was no significant difference in survival outcomes regardless of which method was used. In practice, doctors based the majority of their treatment decisions (73.5%) on liquid biopsy results when both were available.
The Role of AI and Large-Scale Data
Personalized medicine generates enormous amounts of data: genomic sequences, medical histories, lifestyle information, environmental exposures, and even wearable device readings. Making sense of all that data at once is where artificial intelligence comes in. AI systems can analyze complex, overlapping datasets to identify patterns that help predict how individual patients will respond to treatment. This is especially useful for finding subgroups of patients who respond unusually well or poorly to a given therapy, groups too small or too subtle for traditional clinical studies to detect.
The largest effort to build this kind of dataset in the United States is the NIH’s All of Us Research Program, which has enrolled more than 849,000 participants and made data from over 633,000 of them available to researchers. The program has sequenced the whole genomes of more than 414,000 participants, identifying over 1.2 billion genetic variants, including 200 million that had never been reported before. It also collects wearable device data from nearly 60,000 participants and has made a deliberate effort to include underrepresented populations, including American Indian and Alaska Native communities. The goal is to build a research foundation diverse enough to make personalized medicine work for everyone, not just the populations historically overrepresented in medical studies.
Gene Editing for Ultra-Rare Diseases
At the far end of the personalized medicine spectrum, researchers are developing treatments built for a single patient. In a landmark case at Children’s Hospital of Philadelphia, an infant named KJ became the first person treated with a personalized CRISPR gene-editing therapy. KJ was born with severe CPS1 deficiency, a rare metabolic disorder in which the body cannot properly remove ammonia from the blood. The research team designed a CRISPR-based treatment tailored to KJ’s specific genetic mutation. This approach is being expanded to other urea cycle disorders and rare genetic conditions, though it remains in early stages and is limited to cases where no other treatment options exist.
Cost and Access Challenges
The cost of genomic sequencing, the technology underpinning much of personalized medicine, has dropped dramatically. Sequencing costs fell 61% over a recent four-year period in one tracked program. But sequencing is only part of the expense. Analyzing the data through bioinformatics can account for 21% to 58% of total costs, depending on how complex the analysis needs to be. A full genome sequence with standard analysis currently costs roughly the equivalent of $2,700 to $5,500 USD, with more complex cases running higher.
Insurance coverage for genetic testing remains inconsistent. Some tests, like pharmacogenomic panels for common drugs, are increasingly covered. Others, particularly for rarer conditions or newer applications, may require prior authorization or out-of-pocket payment. The practical reality is that access to personalized medicine still depends partly on where you live, what insurance you carry, and whether your healthcare system has integrated genomic testing into routine care. As costs continue to fall and more drugs require companion diagnostics for prescribing, that gap is narrowing, but it hasn’t closed.